FDA Approves CALCIUM ACETATE — Chartwell RX LLC
Chartwell RX LLC announced FDA approval for its generic Calcium Acetate oral tablets, positioning the company to enter the competing marketplace for phosphate binders used in chronic kidney disease treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed